Literature DB >> 8096777

Plasma neurotransmitters throughout an oral glucose tolerance test in non-depressed essential hypertension patients.

F Lechín1, B van der Dijs, M Lechín, H Jara, A Lechín, S Báez, B Orozco, I Rada, A Cabrera, L Arocha.   

Abstract

The oral glucose tolerance test (OGTT) with plasma neurotransmitter assays and blood pressure measurements were performed on 68 hypertensive (A and B) and 68 paired normal controls (group C). Those patients who failed to show significant or persistent blood pressure reductions throughout OGTT constitute group A (37 subjects); and those who did show significant and persistent reductions constitute group B (31 subjects). The purpose of this study was to assess if there were any significant differences between those patients whose blood pressure levels normalized throughout OGTT and those who didn't and, further, compare them to their controls. In group A, noradrenaline (NA) was high at the 0' (fasting) period, increasing further at 60' and 90'; however, circulating serotonin (p5HT) did not vary throughout OGTT. Group B, although showing high NA at 0', did not show rises afterwards; whereas, significant and sustained p5HT rises registered throughout postprandial periods. In group C, both p5HT and plasma NA showed significant and sustained increases. Therefore, the NA/p5HT ratio is higher in A, than in B and C. Group A patients were awake and alert throughout. Group B patients were mostly drowsy and many slept light and intermittently. Group C subjects slept throughout, dreaming and showing rapid eye movements. Our findings suggest that the hypertensive syndrome is most severe in those patients who do not show a rise in postprandial circulating serotonin (parasympathetic activity), group A, than those who do exhibit such a rise, group B.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096777     DOI: 10.3109/10641969309041621

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  5 in total

1.  Effects of amantadine on circulating neurotransmitters in healthy subjects.

Authors:  Fuad Lechin; Bertha van der Dijs; Betty Pardey-Maldonado; Jairo E Rivera; Scarlet Baez; Marcel E Lechin
Journal:  J Neural Transm (Vienna)       Date:  2010-02-04       Impact factor: 3.575

Review 2.  Central nervous system plus autonomic nervous system disorders responsible for gastrointestinal and pancreatobiliary diseases.

Authors:  Fuad Lechin; Bertha van der Dijs
Journal:  Dig Dis Sci       Date:  2008-07-16       Impact factor: 3.199

3.  Irritable bowel syndrome, depression, and Th-1 autoimmune diseases.

Authors:  Fuad Lechin; Bertha van der Dijs
Journal:  Dig Dis Sci       Date:  2006-12-08       Impact factor: 3.487

4.  Amantadine reduces glucagon and enhances insulin secretion throughout the oral glucose tolerance test: central plus peripheral nervous system mechanisms.

Authors:  Fuad Lechin; Bertha van der Dijs; Betty Pardey-Maldonado; Jairo E Rivera; Marcel E Lechin; Scarlet Baez
Journal:  Diabetes Metab Syndr Obes       Date:  2009-12-02       Impact factor: 3.168

5.  Anorexia nervosa depends on adrenal sympathetic hyperactivity: opposite neuroautonomic profile of hyperinsulinism syndrome.

Authors:  Fuad Lechin; Bertha van der Dijs; Betty Pardey-Maldonado; Jairo E Rivera; Scarlet Baez; Marcel E Lechin
Journal:  Diabetes Metab Syndr Obes       Date:  2010-09-09       Impact factor: 3.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.